Product Description

🔹 Product Overview
Enhertu 100 mg Injection is a prescription targeted cancer therapy (antibody-drug conjugate) used in the treatment of certain HER2-positive and HER2-mutant cancers.
Contains Trastuzumab Deruxtecan (fam-trastuzumab deruxtecan-nxki), a modern oncology medicine designed to directly target cancer cells.
It is administered only as an intravenous infusion in hospitals under specialist supervision.

🔹 Key Uses
Enhertu is used in adult patients for specific advanced cancers such as:
HER2-positive breast cancer (metastatic or unresectable)
HER2-low breast cancer after prior treatment
Advanced stomach (gastric) cancer
Non-small cell lung cancer (HER2-mutant cases)

🔹 Composition
Active ingredient: Trastuzumab Deruxtecan 100 mg
Drug class: HER2-directed antibody-drug conjugate (ADC)
Combines targeted therapy + chemotherapy in a single molecule

🔹 How It Works
Binds specifically to HER2 receptors on cancer cells
Delivers a chemotherapy payload directly inside tumor cells
Helps destroy cancer cells while limiting damage to nearby healthy tissue
May also affect nearby cancer cells (“bystander effect”)

🔹 Key Benefits
Highly targeted modern oncology therapy
Helps slow or stop cancer progression in HER2-related tumors
May improve survival outcomes in advanced cancer cases
Given as intermittent IV infusion under medical supervision
Used when other treatments are no longer effective

🔹 Dosage and Administration
Administered only by healthcare professionals in a hospital setting
Given as an IV infusion every 3 weeks (cycle-based therapy)
Dose and duration depend on cancer type and patient response
Regular monitoring of blood tests and lung function is required

🔹 Possible Side Effects
Nausea and vomiting
Fatigue and weakness
Hair loss
Low blood counts (risk of infection)
Loss of appetite
Diarrhea or constipation
Serious risk: interstitial lung disease (lung inflammation)
Possible heart-related effects in some patients

🔹 Precautions
Must be used under strict oncology supervision only
Regular lung and heart monitoring is essential
Not recommended during pregnancy or breastfeeding
Patients should immediately report cough, breathing difficulty, or fever
Avoid self-medication (hospital-only administration)